PHR: Research Narrative Radiation therapy is efficacious for many cancers but only partially effective, or totally ineffective for many others. The National Cancer Institute has issued a request for multi-institutional teams to improve the potency of radiation and expand its repertoire of responsive tumors through formation of a Radiation Oncology Biology- Integration Network (“ROBIN”). In response, scientists and clinicians from the Dana-Farber/Harvard Cancer Center in Boston have joined forces with their counterparts at the University of California, San Francisco to propose a Harvard/UCSF Robin Center.

PI_NAMEs: HAAS-KOGAN, DAPHNE A. (contact);MICHOR, FRANZISKA

PROGRAM_OFFICER_NAME: VIKRAM, BHADRASAIN

PROJECT_TERMS: Accounting;Address;Adult;Advisory Committees;Advocate;Anatomy;Artificial Intelligence;Award;Biological;Biological Markers;Biology;Boston;California;Cancer Biology;cancer cell;Cancer Center;cancer genetics;cancer research center director;Cells;Child;Childhood;Childhood Glioma;Childhood Solid Neoplasm;Clinical;Clinical Investigator;clinical material;Clinical Trials;Clinical Trials Network;cohort;Collection;Communities;Comprehensive Cancer Center;Computational Biology;Core Facility;Credentialing;Daphne plant;Data;data integration;data modeling;Data Science;Data Set;design;Development;diffuse midline glioma;Discipline;Doctor of Medicine;Doctor of Philosophy;dosimetry;Education;Elements;Evolution;experience;External Beam Radiation Therapy;Extramural Activities;Face;Family;Funding;Future;General Population;Genetic;genomic data;Heterogeneity;high risk;Image;improved;Infrastructure;Infrequent Neoplasm;insight;Institution;International;Investigational Therapies;Late Effects;Machine Learning;Malignant Childhood Neoplasm;Malignant Neoplasms;mathematical model;Medical;metaiodobenzylguanidine;Methodology;Mission;Modality;Molecular;multimodality;multiscale data;Mutation;National Cancer Institute;National Clinical Trials Network;neoplastic cell;Neuroblastoma;novel;Oncology;Outcome;outreach program;Patient advocacy;Patients;Pediatric Neoplasm;Persons;physical science;Physics;Pilot Projects;Population;Positioning Attribute;Process;Productivity;professor;programs;prospective;Quality of life;Radiation;radiation during childhood;Radiation Oncologist;Radiation Oncology;radiation resistance;radiation response;Radiation therapy;Radiobiology;Radiogenomics;Radiopharmaceuticals;radioresistant;Records;Regimen;Research;Research Personnel;Research Project Grants;Resistance;Resources;response;Robin bird;Sampling;San Francisco;Scientist;skills;Solid Neoplasm;spatiotemporal;Specific qualifier value;Specimen;standard of care;Students;Sum;Technology;Testing;Toxic effect;Training;Training Programs;treatment response;tumor;tumor heterogeneity;Tumor Tissue;tumor-immune system interactions;Universities;Variant;Work

PROJECT_TITLE: Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Biomedical Imaging;Cancer

ORG_CITY: LA JOLLA

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: SCRIPPS RESEARCH INSTITUTE, THE

ORG_STATE: CA

PHR: Project Narrative Recent breakthroughs in targeted covalent inhibitors are revolutionizing the treatment and prognosis of many cancers, however, people have been reluctant to develop new covalent inhibitors due to the fear of off-target toxicity. This proposal aims to combine chemoproteomic and tissue imaging approaches to establish a 3D, whole-body platform for comprehensive identification of on- and off- targets of covalent drugs in vivo. The resulting technologies and data will have an immediate and transformative impact on the development and refinement of cancer therapies.

PI_NAMEs: CRAVATT, BENJAMIN F;YE, LI  (contact)

PROGRAM_OFFICER_NAME: OSSANDON, MIGUEL

PROJECT_TERMS: 3-Dimensional;Acceleration;Adopted;Affinity;Agammaglobulinaemia tyrosine kinase;Animals;Antineoplastic Agents;Aspirin;Binding;Body System;Brain;bropirimine;cancer therapy;Cardiotoxicity;Cardiovascular system;cell type;Cells;cellular targeting;Chemicals;Chemistry;chemoproteomics;Clinical;Communities;Data;data streams;design;Development;Dose;drug discovery;Drug or chemical Tissue Distribution;Drug Targeting;Drug toxicity;Ensure;Enzyme Inhibitor Drugs;Enzymes;Epidermal Growth Factor Receptor;FAAH inhibitor;Fibroblast Growth Factor Receptors;Fluorescence;Foundations;Fright;Future;Goals;Heart;high resolution imaging;Histologic;Human;Hybrids;Image;imaging approach;imaging modality;In Situ;in vivo;in vivo imaging;inhibitor;interest;JAK3 gene;kinase inhibitor;Knowledge;KRAS2 gene;Label;lead optimization;Link;Malignant Neoplasms;Mammals;Maps;Methods;Modeling;Molecular;Mus;Nature;Neurons;Oncogenic;Oncology;Organ;Organism;Penicillins;Persons;Pharmaceutical Preparations;Phosphotransferases;Positron-Emission Tomography;preference;Prognosis;programs;Proteins;Proteomics;Protocols documentation;Recording of previous events;Resolution;scale up;screening;side effect;Signal Transduction;small molecule;Specificity;Structure;Structure-Activity Relationship;success;Techniques;Technology;technology development;Therapeutic Index;Thinness;Tissue imaging;Tissues;tool;Toxic effect;Translations;Tyrosine Kinase Inhibitor;whole body imaging

PROJECT_TITLE: A platform to identify in vivo targets of covalent cancer drugs in 3D tissues


FUNDING_MECHANISM: RESEARCH CENTERS

NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Climate-Related Exposures and Conditions;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Human Genome;Skin Cancer

ORG_CITY: NEW HAVEN

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: CORE B – BIOSPECIMEN CORE: PROJECT NARRATIVE Biospecimen Core (Core B), provides a variety of clinically annotated samples (tumor, normal skin, plasma, peripheral blood lymphocytes, tumor infiltrating lymphocytes, serum, short term cultures, DNA and RNA) to SPORE investigators and other collaborators at Yale and outside of Yale. Integration with Core C for storage of data is key to maximizing utilization of specimens and distribution of samples is governed by a Tissue Committee. The Core is central to all the activities of YSPORE and well integrated with pathology and clinical services at Yale Cancer Center.

PI_NAMEs: HALABAN, RUTH  (contact)

PROJECT_TERMS: Address;Adult;Antibodies;Archives;Area;Basic Science;bench to bedside;Bioinformatics;Biological;Biological Specimen Banks;biomarker discovery;Biometry;Biostatistics Core;Biotechnology;Cancer-Predisposing Gene;career;Cell Culture Techniques;Cell Extracts;Cells;central database;chromatin modification;Clinical;Clinical Data;Clinical Services;Clinical Trials;clinically relevant;Collaborations;Collection;Consent;Core Facility;cost effective;Cytometry;Data;Data Storage and Retrieval;data warehouse;Dermatopathology;Development;Dimethyl Sulfoxide;DNA;Ensure;Epidemiology;Evaluation;exome;Family;follow-up;Freezing;Future;Gene Expression Profiling;Genetic;genome analysis;genomic data;Genomics;Goals;Health Insurance Portability and Accountability Act;Health protection;Hospitals;Human;Image;Immune response;Infrastructure;innovation;Institution;Laboratories;Lesion;Link;liquid crystal polymer;Liquid substance;Lymphocyte;Measures;melanocyte;Melanoma;Melanoma Cell;Melanoma patient;Melanoma Tumor;Methods;Methylation;Molecular;Molecular Analysis;Mutation;Mutation Analysis;nano-string;Necrosis;neoplastic cell;Nevus;new therapeutic target;Newborn Infant;Nitrogen;Oligonucleotides;operation;Paraffin;Pathologic;Pathology;patient health information;Patients;peripheral blood;Peripheral Blood Lymphocyte;Peripheral Blood Mononuclear Cell;Plasma;Plasmids;Policies;preclinical study;Procedures;Process;programs;promoter;Proteomics;quality assurance;Quality Control;Reagent;Recording of previous events;Research Infrastructure;Research Personnel;Research Project Grants;Resource Sharing;Resources;Review Committee;RNA;Sampling;Scientist;Secure;Security;Serum;Services;Skin;Skin Cancer;Slide;Specimen;Sun Exposure;Surgical Pathology;System;Testing;The Cancer Genome Atlas;Tissue Banks;Tissues;transcriptome sequencing;Translational Research;translational study;tumor;tumor microenvironment;tumor registry;Tumor Tissue;tumor-immune system interactions;Tumor-Infiltrating Lymphocytes;United States National Institutes of Health;Yale Cancer Center

PROJECT_TITLE: Core B: Biospecimen Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Gene Therapy;Genetics;Hematology;Immunotherapy;Lymphatic Research;Lymphoma;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: PHILADELPHIA

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PHR: Narrative (PROJECT 1) The goal of this project is to address major challenges and unmet needs of chimeric antigen receptor or “CAR” T cells that currently limit treatment success in patients with blood and lymph node cancers. We propose to identify critical characteristics of effective CAR T cell products to obtain information useful in optimizing therapy and then engineer around resistance mechanisms using cutting-edge gene editing tools with the goal of creating CAR T cells more effective at inducing long-lasting remissions. The proposed research is relevant to public health because it will help increase the potency of CAR T cells used to treat chemotherapy-resistant cancers, which may make this strategy viable and efficacious for many more patients.

PI_NAMEs: FRAIETTA, JOSEPH ANTHONY (contact)

PROJECT_TERMS: Ablation;Acute Lymphocytic Leukemia;Address;Adopted;Adoptive Immunotherapy;Antigen Receptors;Antigens;Autoimmune Diseases;Automobile Driving;Award;B lymphoid malignancy;B-Cell Acute Lymphoblastic Leukemia;B-Cell Leukemia;B-Cell NonHodgkins Lymphoma;biobank;Biological Assay;Biological Markers;Biology;Blood;cancer immunotherapy;CAR T cell therapy;CBL gene;CD19 Antigens;CD19 gene;Cell Culture Techniques;Cell Physiology;Cells;cellular engineering;Characteristics;Chemoresistance;chimeric antigen receptor;chimeric antigen receptor T cells;Chronic Lymphocytic Leukemia;Clinic;Clinical;Clinical Trials;clinically actionable;cohort;Collaborations;CRISPR/Cas technology;Critical Pathways;CTLA4 gene;cytokine;Data;design;Development;Disease remission;Dose;Engineering;exhaust;Exhibits;experience;experimental study;first-in-human;Flow Cytometry;follow-up;Future;gene editing technology;Gene Targeting;Genes;Genetic;Genetic Transcription;genome editing;Goals;head-to-head comparison;Hematological Disease;Heterogeneity;Human;Immune;immune checkpoint;Immunologics;Immunotherapy;improved;improved outcome;in vivo;Infiltration;Infusion procedures;inhibitor;innovation;Investigation;Knock-out;Laboratories;Lead;leukemia;Libraries;Link;Lupus;Lymphocyte;Malignant Lymph Node Neoplasm;Malignant lymphoid neoplasm;Malignant Neoplasms;manufacture;manufacturing process;Mediator;Modeling;mouse model;multiple omics;neoplastic cell;new technology;next generation;novel;Outcome;Pathway interactions;Patients;Population;PRDM1 gene;pre-clinical;prevent;programmed cell death protein 1;Proliferating;Property;Proteins;PTPN6 gene;Public Health;Publishing;Reagent;Receptor Signaling;Recurrent disease;Refractory;refractory cancer;Relapse;Research;Resistance;resistance mechanism;Resolution;response;Safety;safety assessment;Sampling;Science;Series;Serum;Specific qualifier value;Structure;success;synthetic biology;T-Cell Development;T-Cell Proliferation;T-Cell Receptor;T-Cell Receptor Therapy;T-Lymphocyte;T-Lymphocyte Subsets;Technology;Testing;Therapeutic;Therapeutic Index;Time;tool;Toxic effect;trafficking;Translating;Treatment Failure;treatment optimization;tumor;Tumor Tissue;vector;Veins;Work;Xenograft Model

PROJECT_TITLE: From the Past to the Future: Chimeric Antigen Receptor T cells for Lymphoid Malignancies


ADMINISTERING_IC: GM

ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Nanotechnology;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Embryonic - Human

ORG_CITY: HADLEY

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: UNIVERSITY OF MASSACHUSETTS AMHERST

ORG_STATE: MA

PHR: PROJECT NARRATIVE The project is relevant to public health because it is expected to deliver cell-control tools based on microenvironmental pH modulation with orders-of-magnitude-improved spatiotemporal resolutions compared to conventional diffusion-based approaches. Such outcomes are critical to advancing bioengineering development and enabling downstream applications in cell/tissue engineering, synthetic morphology, drug delivery, and therapeutics including cardiovascular protection, cardiac/cancer therapeutics (e.g., regenerative medicine), and anti-cancer strategies. Therefore, the project is relevant to the part of the NIH’s mission that pertains to reducing illness and disability.

PI_NAMEs: PING, JINGLEI  (contact)

PROGRAM_OFFICER_NAME: SALVADOR MORALES, CAROLINA

PROJECT_TERMS: Address;Advanced Development;anti-cancer;Behavior;Bicarbonates;Biomedical Engineering;Buffers;Carbon Dioxide;Cardiac;Cardiac Myocytes;Cardiovascular system;cell behavior;Cell model;Cell Physiology;Cells;Cellular biology;Chemicals;Communication;Development;Devices;Diffusion;disability;Drug Delivery Systems;Failure;Goals;graphene;improved;Malignant Neoplasms;Metabolism;meter;Methods;Microelectrodes;Microscopic;Mission;Morphogenesis;Morphology;nanomaterials;neoplastic cell;Optics;Outcome;Pathogenesis;pH gradient;Positioning Attribute;Property;Public Health;Reaction Time;Regenerative Medicine;Regulation;Resolution;Signal Transduction;spatiotemporal;System;Techniques;Testing;Therapeutic;Time;Tissue Engineering;tool;Transducers;two-dimensional;United States National Institutes of Health

PROJECT_TITLE: Cell Control via Spatiotemporal Microenvironmental pH Modulation


ADMINISTERING_IC: NS

ED_INST_TYPE: SCHOOLS OF MEDICINE

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Amyotrophic Lateral Sclerosis (ALS);Brain Disorders;Genetics;Neurodegenerative;Neurosciences;Rare Diseases

ORG_CITY: Aurora

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: PROJECT NARRATIVE Many neurological diseases, including ALS, are associated with mutations in proteins that ensure that RNA molecules are located where they are supposed to be. However, the extent to which RNAs are mislocalized in disease settings has not been explored. Here, we will discover which RNA molecules are mislocalized in neurons as a result of ALS, learn about the mechanisms that regulate their localization in healthy cells, and connect ALS patient phenotypes to these molecular localization defects.

PI_NAMEs: RUSS, HOLGER A.;TALIAFERRO, JEFFERSON MATTHEW (contact)

PROGRAM_OFFICER_NAME: GUBITZ, AMELIE

PROJECT_TERMS: Affect;ALS pathology;ALS patients;Amyotrophic Lateral Sclerosis;Axon;Biological Assay;Brain;Cells;Data;Defect;Dendrites;Disease;disease phenotype;Drosophila genus;Engineering;Ensure;Eukaryotic Cell;experimental study;Face;fly;FMR1 gene;Fragile X Syndrome;frontotemporal lobar dementia amyotrophic lateral sclerosis;Genes;Human;Image;Imaging Techniques;insight;Knockout Mice;Label;Language;Learning;Length;live cell microscopy;Location;Mediating;Messenger RNA;meter;Microscopy;Modality;Molecular;molecular phenotype;Molecular Target;Monitor;Morphology;Motor Neurons;Mus;mutant;Mutation;Nervous System Disorder;Neurons;novel;Orthologous Gene;Patients;Phenotype;Physiological;Process;protein function;protein TDP-43;Proteins;Qualifying;Regulation;Reporter;research and development;RNA;RNA Sequences;RNA Transport;RNA-Binding Proteins;Signal Transduction;single molecule;Site;Sorting;Spinal Muscular Atrophy;stem cell biology;stem cell differentiation;Techniques;Testing;therapeutic development;Transcript;transcriptome;transcriptomics;Translating;Visualization

PROJECT_TITLE: Mechanistic analysis of TDP-43-mediated RNA localization in neurons and its misregulation in ALS

STUDY_SECTION: CMND

STUDY_SECTION_NAME: Cellular and Molecular Biology of Neurodegeneration Study Section[CMND]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Data Science;Networking and Information Technology R&D (NITRD);Skin Cancer

PHR: CORE C: PROJECT NARRATIVE With a stellar team of bioinformaticians and biostatisticians, the Core will provide the whole spectrum of analytic support to all SPORE projects and investigators. The Core will ensure that all studies are properly designed and executed and that data are properly managed, analyzed, reported, and published.

PI_NAMEs: MA, SHUANGGE  (contact)

PROJECT_TERMS: Achievement;Address;Applications Grants;Award;Bioinformatics;biomedical data science;Biometry;career;Cells;Characteristics;Clinical Trials;Clinical Trials Design;Collaborations;Communities;Complex;Comprehensive Cancer Center;Computational Biology;cost effective;Data;Data Analyses;Data Collection;data management;database of Genotypes and Phenotypes;Deposition;design;Development;Doctor of Philosophy;early phase clinical trial;Ensure;experience;Faculty;Fostering;Funding;Goals;graduate student;Guidelines;Head and neck structure;Individual;innovation;Leadership;Malignant neoplasm of lung;Malignant Neoplasms;Manuscripts;meetings;Melanoma;Methods;Monitor;Multiomic Data;Network-based;next generation;Pathway interactions;Play;Policies;Postdoctoral Fellow;posters;Preparation;programs;Publications;Publishing;Regulation;Reporting;repository;Research;Research Design;Research Personnel;Role;Science;Services;Skin Cancer;student training;success;System;The Cancer Genome Atlas;Training;Training and Education;United States National Institutes of Health;Visit

PROJECT_TITLE: Core C: Biostatistics and Bioinformatics Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Gene Therapy;Genetics;Hematology;Immunotherapy;Orphan Drug;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

PHR: NARRATIVE (PROJECT 2) This proposal seeks to bring the power of genetically-modified T cell therapy to the treatment of patients with AML using cutting edge genetic engineering approaches. The proposed research is relevant to public health because it addresses the challenges facing physician-scientists in the quest to find and use cancer-specific antigens for immunotherapy and is relevant to those parts of the NCI’s mission that pertain to eliminating suffering and death due to cancer. This work is expected to open new therapeutic horizons in the field of adoptive immunotherapy for AML and new research horizons that could be translated to other malignancies by combining CART cell therapy with gene editing.

PI_NAMEs: GILL, SAAR  (contact)

PROJECT_TERMS: Acceleration;Address;Adoptive Immunotherapy;Alanine;Allogenic;Antibody-drug conjugates;Antigens;B lymphoid malignancy;base editing;Biotechnology;Bone Marrow Purging;CAR T cell therapy;CD19 gene;CD34 gene;CD45 Antigens;Cell Therapy;Cells;Cessation of life;chemotherapy;chimeric antigen receptor;chimeric antigen receptor T cells;clinical development;Clinical Research;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;conditioning;Credentialing;CRISPR/Cas technology;design;Disease;donor stem cell;drug development;engineered T cells;Engineering;Engraftment;Epitopes;Extracellular Domain;Functional disorder;gene editing technology;Gene Modified;Genes;Genetic Engineering;Goals;Hematologic Neoplasms;Hematology;Hematopoietic;Hematopoietic Neoplasms;Hematopoietic Stem Cell Transplantation;Hematopoietic stem cells;Hematopoietic System;HLA Antigens;Human;Immunodeficient Mouse;immunological synapse;Immunotherapy;In Vitro;in vivo;Individual;Infusion procedures;Knock-out;Lead;leukemia;Malignant Neoplasms;Medical;Mission;Multiple Myeloma;Mutagenesis;Mutation;next generation;novel therapeutics;Patients;Pharmaceutical Preparations;Physicians;prevent;Protein Tyrosine Phosphatase;PTPRC gene;Public Health;receptor;Reporting;Research;Resistance;Scientist;screening;self-renewal;Site;Stem cell transplant;stem cells;stemness;Surface;T cell therapy;T-Lymphocyte;Technology;Testing;Translating;Work

PROJECT_TITLE: Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies


FUNDING_MECHANISM: SBIR-STTR RPGS

NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Brain Disorders;Hydrocephalus;Neurosciences;Rare Diseases

ORG_CITY: MADISON

ORG_NAME: MADISON SCIENTIFIC, INC.

ORG_STATE: WI

PHR: PROJECT NARRATIVE Hydrocephalus is a disease of epidemic proportions associated with significant neurologic complications and death, and which represents half of a pediatric neurosurgical practice. Ventricular shunting, the mainstay treatment for hydrocephalus, has significant failure rates secondary to suboptimal gravity-dependent shunt systems, with virtually no improvement in shunt function since invention of the shunt in the 1950s. We propose to complete the development of a “smart shunt” system tailored to meet patient needs by draining in response to sustained intracranial pressure elevation and not in response to gravitational forces from changes in body position, or to transient pressure spikes related to activities of normal daily living, such as coughing, sneezing, and straining.

PI_NAMEs: WANKE, TYLER  (contact)

PROGRAM_OFFICER_NAME: AUBRECHT, TARYN GRACE

PROJECT_TERMS: absorption;Achievement;Activities of Daily Living;Animal Model;Animals;Architecture;Area;body position;Brain;Budgets;Catheters;Cerebral Ventricles;Cerebrospinal Fluid;Cerebrospinal fluid shunts procedure;Cessation of life;Childhood;Communication;Coughing;Custom;Data;debilitating symptom;design;Development;Devices;Diagnostic;Disease;Distal;Drainage procedure;Effectiveness;Ensure;Epidemic;Exclusion;Failure;Feedback;Force of Gravity;Goals;Greater sac of peritoneum;Health Care Costs;Healthcare Systems;Hospitalization;Housing;Hydrocephalus;Implant;implanted sensor;improved;in vivo;Incidence;Individual;Intracranial Hypertension;Intracranial Pressure;invention;Liquid substance;Marketing;Measurement;Measures;Modality;Modeling;Monitor;Neurologic;neurosurgery;novel;Obstruction;operation;Operative Surgical Procedures;Patients;Performance;performance tests;Physiological;Polychlorinated Biphenyls;porcine model;Positioning Attribute;Posture;preclinical study;pressure;pressure sensor;prevent;primary endpoint;prototype;Readiness;Recurrence;Repeat Surgery;Research;response;Risk;safety and feasibility;Sampling;Second Look Surgery;Secondary to;sensor;sensor technology;Shunt Device;Signal Transduction;Sneezing;Specific qualifier value;success;System;Technology;technology platform;Testing;Therapeutic;Time;Translating;transmission process;Ventricular;virtual;wireless communication;Work

PROJECT_TITLE: Development of a Smart Shunt with ICP-feedback for the Treatment of Hydrocephalus

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-NV-C(10)B]


ADMINISTERING_IC: EY

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Eye Disease and Disorders of Vision;Gene Therapy;Genetics;Prevention;Regenerative Medicine;Wound Healing and Care

ORG_CITY: SYRACUSE

ORG_NAME: DUB THERAPEUTICS INC.

ORG_STATE: NY

PHR: Narrative: Worldwide, corneal scars are a leading cause of monocular blindness. Initial wound healing responses can prevent infection but subsequent tissue repair often results in scarring that leads to obstructed vision or blindness. Current preventative measures have unpredictable results and cause well-established adverse events that include cataracts and glaucoma. The current project will prepare a novel self-delivery siRNA-based therapeutic for clinical trials that promotes regenerative healing in the cornea and prevents scar formation, creating a powerful method to combat opacification with a simple eye drop.

PI_NAMEs: WILLIAMS, TERE M. (contact)

PROGRAM_OFFICER_NAME: GOVER, TONY DOUGLAS

PROJECT_TERMS: Adrenal Cortex Hormones;Adverse event;Affect;animal efficacy;Apoptosis;Appearance;Area;Biological Products;blind;Blindness;Cataract;cell type;Cells;Cellular Morphology;Cholesterol;Cicatrix;Clinical;Clinical Trials;Collagen;combat;Computer software;Cornea;corneal epithelium;Corneal Injury;corneal scar;Cyclic GMP;Defect;Dermal;Disease;Dose;Drug toxicity;Economic Burden;efficacy study;Encapsulated;Environment;epithelial wound;Epithelium;experimental study;Eyedrops;Family suidae;Fiber;Fibroblasts;Fibronectins;first-in-human;Fluorescein;Formulation;Funding;Future;Glaucoma;Human;Immune;Immunohistochemistry;improved;In Situ Nick-End Labeling;In Vitro;in vivo;in vivo Model;Infection;Infection prevention;Inflammation;Inflammatory;Injury;insight;Investigation;Investments;Keratoplasty;knock-down;Legal patent;Length;Lipids;manufacture;manufacturing facility;manufacturing process;manufacturing run;manufacturing scale-up;Marketing;Mediator;Methods;Modeling;monocular;Monocular Blindness;mouse model;Mus;nanoparticle;neovascularization;Nerve Regeneration;novel;nuclease;Organ Culture Techniques;Orphan Drugs;Oryctolagus cuniculus;Outcome;Pathway interactions;Patients;Persons;Pharmaceutical Preparations;Pharmacologic Substance;Phase;Phase I Clinical Trials;Population;pre-Investigational New Drug meeting;Preparation;prevent;Prevention;Preventive measure;Process;process optimization;Proliferating;PTPRC gene;Quality of life;regenerative healing;Resistance;response;Safety;scale up;siRNA delivery;Small Business Innovation Research Grant;Small Interfering RNA;Stains;Technology;Therapeutic;Therapeutic Clinical Trial;therapeutic siRNA;tissue repair;Tissues;Toxic effect;Toxicokinetics;Toxicology;Transfection;Transplantation;Trauma;Tubulin;ubiquitin isopeptidase;Vision;Visual impairment;Visually Impaired Persons;Work;wound closure;wound healing;Wound models

PROJECT_TITLE: A single dose anti-scarring therapeutic for the cornea

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-NV-M(12)B]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Prevention;Skin Cancer

PI_NAMEs: STERN, DAVID F (contact)

PROJECT_TERMS: anti-cancer research;Area;Basal cell carcinoma;base;cancer risk;clinical translation;Collaborations;Communities;Coupled;Cutaneous;Dermatology;Development;Diagnosis;Direct Costs;Ensure;Funding;Funding Opportunities;Future;Goals;Grant;Human;innovation;Institution;inter-institutional;interest;Leadership;meetings;Melanoma;multidisciplinary;New York;Oncology;Pilot Projects;Play;Prevention;Privatization;Productivity;Prognosis;Program Research Project Grants;programs;Recommendation;Reproduction spores;Research;Research Activity;research and development;Research Personnel;Research Project Grants;Resource Development;Role;Skin Cancer;skin squamous cell carcinoma;Source;success;technology development;Translational Research;United States National Institutes of Health;Universities;Yale Cancer Center

PROJECT_TITLE: Developmental Research Program (DRP)


FUNDING_MECHANISM: OTHER RESEARCH-RELATED

NIH_SPENDING_CATS: Cancer;Palliative Care

ORG_CITY: BOSTON

ORG_NAME: DANA-FARBER CANCER INST

PHR: PROJECT NARRATIVE We propose to continue a successful three-day virtual workshop on research skills for early-career PIs to address observed decreases in the early-career cancer research workforce. The workshop will teach advanced research methods, leadership skills, and professional resiliency, with two elective tracks to meet diverse needs.

PI_NAMEs: GREER, JOSEPH ANDREW;PIRL, WILLIAM F (contact)

PROGRAM_OFFICER_NAME: ZAHIR, NASTARAN

PROJECT_TERMS: Address;anti-cancer research;Area;Basic Science;Cancer Center;career;Clinical;Collaborations;Communication;Computer software;Course Content;Dana-Farber Cancer Institute;Data Collection;early-career faculty;Education Projects;Educational process of instructing;Educational workshop;Eligibility Determination;Evaluation;evidence base;experience;Face;Faculty;Faculty Workshop;Feedback;follow-up;Funding;Future;General Hospitals;Goals;Grant;Human Resources;improved;Infrastructure;Institution;Interdisciplinary Study;Journals;Leadership;Malignant Neoplasms;Massachusetts;Mission;Modeling;multidisciplinary;Natural Language Processing;Occupational activity of managing finances;Occupations;Oncology;Outcome;Palliative Care;Participant;Patient Recruitments;Performance;Personnel Management;Process;Production;Productivity;programs;Protocols documentation;recruit;Reporting;Research;Research Design;Research Methodology;Research Personnel;Research Training;resilience;Resources;response;Site;skill acquisition;skills;skills training;Spottings;System;Time;Training;Translational Research;trend;United States National Institutes of Health;virtual;Work;Writing

PROJECT_TITLE: Advanced Workshop on Research Skills in Oncology

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Institutional Training and Education Study Section (F)[NCI-F]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Clinical Research;Gene Therapy;Genetics;Hematology;Immunotherapy;Nanotechnology;Orphan Drug;Rare Diseases

PHR: PROJECT NARRATIVE (PROJECT 3) This project is relevant to public health because it evaluates new strategies to improve duration-of-response to CAR T cell therapy in multiple myeloma patients, a largely incurable blood cancer for which current-generation CAR T cells are only partially effective. The project is relevant to those parts of the NCI's mission that pertain to eliminating suffering and death due to cancer. This work is expected to open new therapeutic approaches in the field of adoptive immunotherapy for multiple myeloma and new research horizons that could be translated to other malignancies.

PI_NAMEs: MILONE, MICHAEL C. (contact)

PROJECT_TERMS: Adoptive Immunotherapy;advanced disease;Antigen Targeting;Antigen-Presenting Cells;Antigens;Autologous;B-Lymphocytes;Bone Marrow;cancer type;CAR antigen;CAR T cell therapy;CD19 gene;Cell Maturation;Cells;cellular transduction;Cessation of life;chimeric antigen receptor T cells;Clinical;Clinical Data;Clinical Research;Clinical Trials;cost;cost effective;cytokine;Data;Dendritic Cells;Development;early phase clinical trial;FDA approved;Generations;Genes;genome editing;Goals;Harvest;Hematologic Neoplasms;Hematopoietic Neoplasms;Homing;Human;Immune response;Immunocompetent;Immunologic Surveillance;improved;In complete remission;in vivo;Infiltration;Inflammatory;Infusion procedures;Interleukin 2 Receptor;Interleukin-2;lentivirally transduced;Lentivirus Vector;Ligands;lipid nanoparticle;Lymphocyte;Maintenance;Malignant Neoplasms;manufacture;Marrow;Messenger RNA;Mission;Modeling;Modernization;mouse model;mRNA lipid nano particle vaccine;Multiple Myeloma;Mutate;Myelogenous;Myeloid Cells;novel;novel strategies;novel therapeutic intervention;Outcome;Patients;Peripheral Blood Lymphocyte;pharmacologic;Phase I Clinical Trials;phase I trial;Phenotype;Plasma Cells;Population;pre-clinical;Pre-Clinical Model;preclinical study;predict clinical outcome;predicting response;prevent;prime editing;Progressive Disease;Proliferating;Public Health;Publishing;Refractory;Relapse;relapse prediction;relapse prevention;relapse risk;Research;response;Safety;safety and feasibility;safety assessment;safety testing;Science;Signal Transduction;Solid Neoplasm;Source;Specificity;success;System;T cell response;T-Cell Activation;T-Lymphocyte;technology platform;trafficking;transduction efficiency;Translating;translational medicine;Translational Research;Treatment Failure;tumor-immune system interactions;Vaccination;Work;Xenograft Model

PROJECT_TITLE: Improving response durability after CAR T cell therapy for multiple myeloma


PROJECT_TERMS: African American;Appointment;Award;Biological;Biology;Black race;Cancer Biology;cancer risk;cancer therapy;career;career development;Charge;clinical translation;Community Clinical Oncology Program;Cutaneous;Dermatology;Development;Diagnosis;disadvantaged background;Doctor of Philosophy;experience;Faculty;Faculty Recruitment;Funding;Goals;Grant;Hispanic;Human;immunomodulatory therapies;Individual;Latino;Malignant Neoplasms;Melanoma;Mentors;Modality;multidisciplinary;Oncologist;Oncology;pre-clinical;Prevalence;Prevention;Process;Productivity;Prognosis;prognostication;programs;Publications;recruit;Research;Research Personnel;Risk Assessment;Scientist;Services;Skin Cancer;Solid Neoplasm;success;Therapeutic;Time;Training;Translational Research;Woman;Yale Cancer Center

PROJECT_TITLE: Career Enhancement Program (CEP)


ED_INST_TYPE: SCHOOLS OF PHARMACY

NIH_SPENDING_CATS: Biotechnology;Cancer;Immunotherapy

ORG_CITY: LUBBOCK

ORG_DEPT: PHARMACOLOGY

ORG_NAME: TEXAS TECH UNIVERSITY HEALTH SCIS CENTER

ORG_STATE: TX

PHR: Project Narrative This proposal will identify novel mechanisms by which liposomes are metabolized within the body and will determine metabolites that alter immune function and tumor growth. The new knowledge generated is expected to lead to the development of new cancer drug formulations that are both safer and more effective. This proposal will also test new formulations of liposomal doxorubicin containing cholesterol analogs for the treatment of cancer. Our results have the potential to have an immediate clinical impact by swiftly translating into clinical trials. Since dysfunction in lipid metabolism is implicated in other health conditions, the application of this knowledge extends beyond cancer therapy.

PI_NAMEs: LA-BECK, NINH  (contact);ZHANG, QISHENG

PROGRAM_OFFICER_NAME: BOURCIER, KATARZYNA

PROJECT_TERMS: 27-hydroxycholesterol;Address;analog;anti-cancer;anti-cancer therapeutic;antigen-specific T cells;Antineoplastic Agents;Attenuated;biophysical properties;Blood Cells;cancer infiltrating T cells;Cancer Model;Cancer Patient;cancer therapy;Cell Physiology;Cells;chemotherapy;Cholesterol;cholesterol analog;Cholesterol Homeostasis;Clinical;Clinical Trials;Cytotoxic Chemotherapy;Data;design;Development;Disease;Doxorubicin;Drug Carriers;Drug Delivery Systems;Drug Formulations;Drug Kinetics;Drug toxicity;Encapsulated;Enzymes;Failure;FDA approved;Functional disorder;Health;Human;Hydroxycholesterols;Immune;immune function;Immune response;Immune system;Immune System Diseases;Immunologic Tests;Immunologics;immunoregulation;Immunosuppression;Immunotherapy;improved;In Vitro;in vivo;Inflammatory;inhibitor;Interferon Type II;Knockout Mice;Knowledge;lipid metabolism;lipid nanoparticle;liposomal delivery;Liposomal Doxorubicin;liposomal formulation;Liposomes;Macrophage;Malignant Neoplasms;Mediator;Membrane;Meta-Analysis;Metabolic;Metabolic Pathway;Metabolism;Mixed Function Oxygenases;Modeling;Molecular;mouse model;Mus;nanoparticle drug;new therapeutic target;Normal tissue morphology;novel;novel anticancer drug;objective response rate;Pathogenesis;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;Pharmacology;Phospholipids;Phytosterols;Production;Progression-Free Survivals;Property;randomized, clinical trials;Reporting;response;Role;Safety;screening;Signal Pathway;Signal Transduction;smoothened signaling pathway;Solid Neoplasm;STAT3 gene;STAT6 gene;Sterols;Testing;theories;Therapeutic;Therapeutic Effect;Time;Translating;tumor;Tumor Antigens;tumor growth;Tumor Immunity;tumorigenic;Wild Type Mouse;Work

PROJECT_TITLE: CHOLESTEROL METABOLISM IN THE PHARMACOLOGY OF LIPOSOMAL THERAPEUTICS

STUDY_SECTION: INN

STUDY_SECTION_NAME: Innovations in Nanosystems and Nanotechnology Study Section [INN]


ORG_CITY: BALTIMORE

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: JOHNS HOPKINS UNIVERSITY

ORG_STATE: MD

PHR: Alpha-particle emitter radiopharmaceutical therapy (αRPT) is being administered in a prolonged multi-cycle scheme that severely compromises the potential efficacy of this treatment modality. Dosimetry would make it possible to project potential normal organ toxicity for individual patients so that treatment need not be prolonged for the sake of toxicity evaluation. Our primary objectives is to develop and test dosimetry methodologies that will enable precision medicine/treatment-planning-based αRPT for cancer therapy.

PI_NAMEs: SGOUROS, GEORGE  (contact)

PROGRAM_OFFICER_NAME: CAPALA, JACEK

PROJECT_TERMS: absorption;Adoption;Alpha Particle Emitter;Alpha Particles;Biological;biomarker identification;Cancer Biology;Cancer Patient;cancer therapy;Caring;cell killing;Cell surface;Cells;chemotherapy;Clinical Trials;Clinical Trials Design;Combined Modality Therapy;Conformal Radiotherapy;Data;Disease Progression;Disseminated Malignant Neoplasm;DNA;Dose;dosimetry;Drug Kinetics;effective therapy;Electrons;Equilibrium;Evaluation;High-LET Radiation;Human Experimentation;Image;improved;improved outcome;individual patient;Kinetics;Malignant Neoplasms;Measures;meter;Methodology;Methods;Modality;Modeling;Mutation;Neoplasm Metastasis;Normal tissue morphology;Organ;particle;Pathway interactions;Patients;Pharmaceutical Preparations;Phase;Physics;precision medicine;Predisposition;prevent;Program Research Project Grants;programs;quantitative imaging;Radiation;radiation delivery;Radioactive;Radiobiology;Radiopharmaceuticals;Regimen;repaired;resistance mechanism;response;Rest;Risk;Scheme;side effect;synergism;Testing;Therapeutic;Therapeutic Agents;Three-Dimensional Imaging;Time;Toxic effect;Translating;Treatment Efficacy;treatment planning;treatment responders;treatment response;Treatment-related toxicity;trend;tumor;Tumor Biology;Tumor Cell Biology;tumor progression;Tumor Tissue;Work

PROJECT_TITLE: Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy


PHR: NARRATIVE CORE A: ADMINISTRATIVE AND CLINICAL TRANSLATIONAL CORE The Administrative and Clinical Translational core of this Program Project renewal grant is designed to provide scientific and clinical oversight, IND-enabling regulatory and clinical development expertise, and biostatistical and budgetary structure to support effective operations for each P01 project and core, and to promote project integration and synergies. The essential services provided by Core A include: biostatistical support; fiscal management; all clinical protocol development; IND submissions and maintenance; clinical data management and facilitation of communication between projects, cores, internal and external advisory boards and the NCI to ensure effective execution and integration of all Program projects and core objectives.

PI_NAMEs: JUNE, CARL H. (contact)

PROJECT_TERMS: Achievement;Address;Annual Reports;authority;Basic Science;Biometry;Budgets;Cancer Center;cancer immunotherapy;CAR T cell therapy;Cellular immunotherapy;chimeric antigen receptor T cells;Clinical;Clinical Data;clinical development;Clinical Protocols;clinical research site;clinical translation;clinical trial implementation;Clinical Trials;Collaborations;Communication;Data;data management;data sharing;design;Disease;Doctor of Philosophy;engineered T cells;Ensure;gene-editing approach;Goals;Grant;Hematologic Neoplasms;Human Resources;Infrastructure;innovation;Institution;Leadership;Learning;Letters;Maintenance;medical schools;meetings;Monitor;novel;operation;organizational structure;Pennsylvania;pharmacovigilance;Physician Executives;preclinical development;preservation;programs;Progress Reports;protocol development;Publishing;Registered nurse;Reporting;Research;Research Personnel;response;Role;Safety;Schedule;Scientist;Services;Structure;success;synergism;T cell therapy;Technology;Testing;timeline;Translational Research;Universities;Update

PROJECT_TITLE: Core A: Administrative and Clinical Translational Core


NIH_SPENDING_CATS: Bioengineering;Cancer;Data Science;Machine Learning and Artificial Intelligence;Pediatric;Pediatric Cancer;Radiation Oncology;Rare Diseases

PI_NAMEs: HAAS-KOGAN, DAPHNE A. (contact)

PROJECT_TERMS: Accounting;Achievement;Address;Adult;Advisory Committees;Advocate;Archives;Artificial Intelligence;Award;Biometry;Boston;Cancer Biology;Cells;Client;Clinical;Clinical Research;Clinical Trials;cloud based;Code;Communication;Communication Methods;Communities;Community Services;Computer Models;Dana-Farber Cancer Institute;Daphne plant;Data;Data Science;Data Science Core;Data Set;Databases;Department chair;design;Doctor of Medicine;Doctor of Philosophy;dosimetry;Education and Outreach;Electronic Mail;Electronics;Evaluation;experience;Face;General Population;Genome;Goals;Grant;Hospitals;Image;Institution;Leadership;Logistics;Machine Learning;Malignant Childhood Neoplasm;mathematical model;Medical;meetings;Mission;Molecular;multidisciplinary;Nature;neoplastic cell;Occupational activity of managing finances;Oncology;outreach program;participant enrollment;Patient advocacy;Patients;Pediatric Hospitals;Pediatric Oncology;pediatric patients;Performance;Persons;Pharmacology;physical science;Physics;Pilot Projects;programs;Protocols documentation;Quality of life;Radiation;Radiation Oncology;radiation resistance;radiation response;radioligand;recruit;Reporting;repository;Request for Applications;Research;Research Personnel;Research Project Grants;resistance mechanism;Resource Sharing;Resources;Science;Services;sharing platform;Site;skills;Source;Talents;Technology;Text;theranostics;tool;Training;Videoconferencing;Vision;web site;Woman;Work

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Gene Therapy;Genetics;Immunization;Immunotherapy;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Vaccine Related

PHR: Core B Narrative Core B will support the goals of the three proposed projects by (a), developing and implementing GMP-grade protocols for the manufacture, validation, and cryopreservation of gene-edited hematopoietic stem cells and/or CAR-T cells for use in clinical trials for patients with CLL, NHL, AML, and multiple myeloma and (b), discovering and characterizing novel single-domain (VHH) antibody fragments with improved functionality against project-related targets including CD5, CD45, and BCMA. Public health will be served not only by helping those suffering from these four types of blood cancers, but the methods developed for producing clinical grade gene-edited stem cells and CAR-T cells may prove to have broad application for their use in the treatment of solid malignancies in the future.

PI_NAMEs: SIEGEL, DONALD LAWRENCE (contact)

PROJECT_TERMS: Accreditation;Affinity;Allogenic;Antibodies;B-Lymphocytes;base editing;bench-to-bedside translation;Biological Assay;Biological Products;Blood Component Removal;CAR T cell therapy;CD19 gene;CD34 gene;Cell Therapy;Cells;cellular engineering;Cellular immunotherapy;chimeric antigen receptor;chimeric antigen receptor T cells;Clinical;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Communicable Diseases;Communities;Complement;Core Facility;CRISPR/Cas technology;Cryopreservation;design;Development;Diagnostic;Ensure;experience;first-in-human;Formulation;Foundations;Future;gene function;Genes;Goals;Hematopoietic Neoplasms;Hematopoietic Stem Cell Transplantation;Hematopoietic stem cells;Human;Immunize;Immunoglobulin Fragments;improved;Infiltration;innovation;Institution;Investigational New Drug Application;Investments;Knock-out;Laboratories;laboratory development;Libraries;Llama;Lymphocyte;Malignant Neoplasms;manufacture;manufacturing facility;Marrow;Mediating;Medicine;Methods;Multiple Myeloma;non-Hodgkin's lymphoma patients;novel;Pathology;Patients;Pennsylvania;peripheral blood;Peripheral Blood Lymphocyte;Phage Display;Phase;programmed cell death protein 1;Property;Protocols documentation;PTPRC gene;Public Health;Quality Control;receptor binding;Refractory;Relapse;Resources;Science;Solid;Source;stem cell genes;stem cells;T-Lymphocyte;Technology;Testing;Therapeutic;Universities;Vaccine Production;Validation

PROJECT_TITLE: Core B - Cell Engineering and Manufacturing Facility


ED_INST_TYPE: ORGANIZED RESEARCH UNITS

NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Clinical Research;Colorectal Cancer;Digestive Diseases;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Pain Research;Palliative Care;Patient Safety;Social Determinants of Health

ORG_CITY: WASHINGTON

ORG_DEPT: MISCELLANEOUS

ORG_NAME: GEORGETOWN UNIVERSITY

ORG_STATE: DC

PHR: There is limited knowledge about the patient-reported outcomes and survivorship care needs of persons living with metastatic colorectal cancer. To address this research gap, we will survey 1600 adults living with metastatic colorectal cancer over a one-year period. The goals of this project are to longitudinally document patient-reported outcomes in a diverse cohort, identify high-risk subgroups, and produce the necessary knowledge base to inform multi-level interventions specifically designed for persons living with this disease.

PI_NAMEs: POTOSKY, ARNOLD L (contact)

PROGRAM_OFFICER_NAME: GALLICCHIO, LISA M

PROJECT_TERMS: Address;Adult;Adverse event;Age;anti-cancer research;Area;Behavioral Sciences;California;cancer diagnosis;Cancer Survivor;cancer therapy;care coordination;care costs;care delivery;Caring;Characteristics;Chronic;Clinical;Clinical Oncology;Clinical Trials;cohort;Colorectal Cancer;Common Terminology Criteria for Adverse Events;comorbidity;Data;Data Reporting;design;Development;Diagnosis;Disease;Disseminated Malignant Neoplasm;Distant;Distress;emotional functioning;Enrollment;Ethnic Origin;evidence base;experience;Financial Hardship;follow-up;Fright;Future;gastrointestinal;Goals;health related quality of life;Health Status;Healthcare Systems;high risk;improved;Individual;Information Systems;innovation;Inpatients;integrated care;Intervention;Intervention Studies;Knowledge;knowledge base;Life;Link;Longitudinal Studies;Malignant Neoplasms;Measurement;Medical Records;Medicare claim;metastatic colorectal;Neoplasm Metastasis;neoplasm registry;Neuropathy;New Jersey;novel therapeutics;Observational Study;Outcome;Pain;Palliative Care;Participant;Patient Outcomes Assessments;Patient Recruitments;Patient Selection;Patient Self-Report;Patients;Persons;Pharmacotherapy;Physical Function;Policies;Population;population based;Population Study;Prevalence;prospective;Prospective Studies;Psychometrics;psychosocial;Race;randomized trial;recruit;Registries;Reporting;Research;Sampling;Self Efficacy;Self Management;Severities;sex;Site;Sleeplessness;Social Functioning;social health determinants;Social support;sociodemographic factors;sociodemographics;Subgroup;Supportive care;Surveys;Survivors;survivorship;Symptom Burden;symptom cluster;symptom management;symptomatic improvement;System;Testing;Uninsured Medical Expense;Variant;Work

PROJECT_TITLE: Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Data Science;Machine Learning and Artificial Intelligence;Neuroblastoma;Neurosciences;Pediatric;Pediatric Cancer;Radiation Oncology;Rare Diseases

PI_NAMEs: KOZONO, DAVID  (contact)

PROJECT_TERMS: Acceleration;Adult;Aftercare;age group;Amendment;Appearance;Artificial Intelligence;Autopsy;biobank;Biological Assay;Biopsy;Blood;Blood specimen;California;Cancer Biology;Cancer Center;Caregivers;Characteristics;Child;Childhood;Clinical;Clinical Data;Clinical Research;clinical trial protocol;Clinical Trials;cohort;Collaborations;Collection;Communities;Consent;Data;Data Collection;Data Element;data resource;Data Science;Data Storage and Retrieval;design;diffuse midline glioma;dosimetry;embryo tissue;Ensure;Goals;Hand;Health protection;Heterogeneity;high risk;Image;immune-related adverse events;innovation;Institution;Investigation;Knowledge;Late Effects;Lead;Long-Term Survivors;Malignant Childhood Neoplasm;Malignant Neoplasms;metaiodobenzylguanidine;Molecular;multidimensional data;multimodality;Mutation;National Clinical Trials Network;neoplastic cell;neuro-oncology;Neuroblastoma;novel;Oncology;Operative Surgical Procedures;Parents;Patients;Pediatric Oncology Group;pediatric patients;Performance;Pilot Projects;Procedures;programs;Protocols documentation;Radiation;Radiation exposure;Radiation Oncology;radiation response;Radiation therapy;Radiopharmaceuticals;Recurrence;Reproducibility;Research;Research Project Grants;Resource Sharing;Resources;risk minimization;sample collection;Sampling;San Francisco;Signal Transduction;Site;Solid Neoplasm;Source;standard of care;Standardization;structured data;success;Testing;The Cancer Genome Atlas;Therapeutic Trials;Tissues;tumor;Universities;validation studies;Work

PROJECT_TITLE: Molecular Characterization Trial


NIH_SPENDING_CATS: Cancer;Pediatric;Rural Health

ORG_CITY: INDIANAPOLIS

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: INDIANA UNIVERSITY INDIANAPOLIS

ORG_STATE: IN

PHR: Access to quality cancer education and exposure to the research enterprise for middle and high school teachers, their students, and early undergraduate students has been very limited in Indiana, which has a significant adverse impact on motivating students to pursue careers in biomedical research. The problem is more acute with students from underrepresented populations. Given this, the main goals of this proposal are 1) Prepare middle-level teachers to provide their students with the prerequisite knowledge and dispositions toward medical research; 2) Provide high school teachers with integrated laboratory research experience and curriculum development opportunities to enhance their biology and cancer-related teaching skills and to create excitement for their students for science-related careers; and 3) Provide mentored, high-quality, cancer-focused research experiences along with didactic and professional development workshops to high school and early undergraduate students from underrepresented backgrounds to prepare them for medicine- or cancer-related fields.

PI_NAMEs: BUCK, GAYLE ;NAKSHATRI, HARIKRISHNA  (contact)

PROGRAM_OFFICER_NAME: HUSSAIN, SHADAB FATIMA

PROJECT_TERMS: Acute;Address;anti-cancer research;Area;Benchmarking;Biology;Biomedical Research;Cancer Biology;Cancer Center;cancer education;career;Career Choice;career development;Clinical;cohort;Communities;community engagement;Comprehensive Cancer Center;curriculum development;design;Development;Dimensions;Disadvantaged minority;early adolescence;Education;education pathway;Educational Assessment;Educational Curriculum;Educational process of instructing;Educational workshop;Ensure;Equipment;Evaluation;experience;Exposure to;Faculty;field trip;Future;Goals;Health Sciences;high school;High School Faculty;Indiana;Indiana University Cancer Center;Institution;interest;junior high school;Knowledge;Laboratories;laboratory experience;Laboratory Research;Leadership;lectures;Literature;Malignant Neoplasms;Medical Research;Medicine;meetings;member;Mentors;metropolitan;Middle School Faculty;Mind;minority student;Mission;outreach;Participant;Pathway interactions;Patient Care;pedagogical content;Program Evaluation;programs;prospective;racial minority;recruit;Research;Research Activity;Resources;Rural;Rural Minority;Schools;Science;science education;skills;socioeconomic disadvantage;Source;Structure;Students;success;summer program;support network;teacher;teacher community;Teacher Professional Development;Time;Training;undergraduate student;Underrepresented Populations;Underrepresented Students;Universities;Visit;Work;Youth

PROJECT_TITLE: Educational Pathways for Cancer Research (EPCR)


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Gene Therapy;Genetics;Hematology;Human Genome;Immunotherapy;Orphan Drug;Rare Diseases

PHR: CORE C PROJECT NARRATIVE Core C will support the goals of the three proposed projects in three ways; 1. Developing improved methods to manufacture gene-edited CAR T and HSPC products and transferring these processes to the manufacturing Core B to ultimately translate research bench concepts to bedside therapies; 2. Supporting the three proposed clinical trials by performing specialized assays on product and patient samples to describe product characteristics and safety aspects and to identify the fate of infused CAR T or CD34+ cells to predict and evaluate their impact on disease; 3. Refining and developing new sophisticated analysis platforms for characterizing products and clinical trial samples on a molecular and clonal level.

PI_NAMEs: HERBST-NOWROUZI, FRIEDERIKE  (contact)

PROJECT_TERMS: Acute Myelocytic Leukemia;Applications Grants;Award;base editing;biobank;Biological Assay;CAR T cell therapy;CD19 gene;CD34 gene;Cell Therapy;Cells;Cellular immunotherapy;cellular transduction;Characteristics;chimeric antigen receptor T cells;Clinical;clinical development;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Color;Correlative Study;CRISPR/Cas technology;Cryopreservation;cytotoxicity;Data;Data Collection;Development;digital;Disease;Engraftment;exhaustion;first-in-human;Flow Cytometry;Future;Gene Expression Profile;Gene Modified;gene therapy;gene-editing approach;Genes;Genetic Transcription;genome editing;Goals;Grant;Hematologic Neoplasms;Human Genome;improved;In Vitro;in vitro Assay;in vivo;Individual;Informed Consent;Infusion procedures;Knock-out;Laboratories;Laboratory Study;Lentivirus;Leukapheresis;Malignant lymphoid neoplasm;manufacture;manufacturing facility;manufacturing process;Methods;Molecular;Multiple Myeloma;Mycoplasma;next generation;novel;Patient-Focused Outcomes;Patients;Phase I Clinical Trials;Phenotype;Population;pre-clinical;Procedures;Process;process optimization;product development;programs;Protocols documentation;PTPRC gene;Refractory;Regulation;Relapse;Research;Research Personnel;Resources;response;Safety;Sampling;scale up;Science;self-renewal;Services;single-cell RNA sequencing;System;T cell differentiation;T cell therapy;T-Lymphocyte;Technical Expertise;Technology;Technology Transfer;technology validation;Testing;Therapeutic;tissue culture;transcriptome;transduction efficiency;Translating;translational study;tumor;Validation;Work

PROJECT_TITLE: CORE C Technology Implementation/Development and Correlative Sciences


ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

PHR: Overall: Narrative The overall goal of this program project application is to find treatments for the hamartoma syndromes, and the common cancers in which these same genes (TSC1, TSC2, LKB1, PTEN) are involved. Please see individual Projects and the Core for each Project Narrative.

PI_NAMEs: KWIATKOWSKI, DAVID J. (contact)

PROGRAM_OFFICER_NAME: MAAS, STEFAN

PROJECT_TERMS: Adult;Alleles;Bannayan Syndrome;Cell division;Cell Line;cell preparation;Cells;clinical care;Critical Pathways;Dependence;Development;Drosophila genus;Event;Frequencies;gene function;Genes;Genetic;Genetic Transcription;Germ Lines;Germ-Line Mutation;Goals;Growth;Hamartoma;human induced pluripotent stem cells;Individual;inhibitor;jun Oncogene;Kidney;loss of function mutation;Malignant Neoplasms;Metabolic;Modeling;Molecular;mTOR Inhibitor;mTOR Signaling Pathway;Multiple Hamartoma Syndrome;Mutation;novel;novel therapeutic intervention;novel therapeutics;Oncogenic;Organoids;Pathogenesis;Pathway interactions;Peutz-Jeghers Syndrome;Phosphotransferases;Program Research Project Grants;programs;PTEN gene;Regulation;Renal Angiomyolipoma;response;Ruvalcaba syndrome;Secondary to;Signal Pathway;Signal Transduction;STK11 gene;Substrate Interaction;Syndrome;Technology;TFE3 gene;The Cancer Genome Atlas;Tissues;transcription factor;TSC1 gene;TSC2 gene;Tuberous Sclerosis;tumor;Tumor Suppressor Genes;Tumor Suppressor Proteins;United States National Institutes of Health

PROJECT_TITLE: Molecular Pathogenesis of the Hamartoma Syndromes


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Cancer Genomics;Data Science;Genetics;Human Genome;Machine Learning and Artificial Intelligence;Neurosciences;Pediatric;Pediatric Cancer;Precision Medicine;Radiation Oncology;Rare Diseases

PROJECT_TERMS: Adult;anti-cancer;Artificial Intelligence;Attention;Autopsy;Biological Markers;Biology;Biopsy;Cancer Biology;cancer cell;cancer genomics;cell type;Cells;Cessation of life;Child;Childhood;Chromatin;Clinical;Clinical Trials;cohort;Collection;Complement;Complex;Computer Models;Daphne plant;Data;Data Analyses;Data Science;Data Science Core;Data Set;demographics;Development;Diagnosis;differential expression;diffuse midline glioma;DNA;DNA Repair Pathway;Doctor of Medicine;Doctor of Philosophy;dosimetry;Elements;Enzymatic Biochemistry;Epigenetic Process;epigenomics;Equilibrium;Evaluation;Evolution;Fostering;Funding;Genetic;Genomics;Gifts;Goals;health related quality of life;Heterogeneity;Histopathology;Image;insight;Laboratory Research;Leadership;Link;longitudinal dataset;macroglia;Malignant Childhood Neoplasm;Malignant Neoplasms;Matched-Pair Analysis;Methodology;Methods;MicroRNAs;Modality;Molecular;Mutation;neoplastic cell;neural;Neurocognitive;Normal Cell;Normal tissue morphology;oligodendrocyte progenitor;Oncologist;Operative Surgical Procedures;Outcome Assessment;Parents;Pathway interactions;Patient Outcomes Assessments;patient population;Patients;Pediatric Neoplasm;Population;Positioning Attribute;precision medicine;programs;prospective;Proteomics;Quality of life;Radiation;radiation during childhood;Radiation Oncologist;Radiation Oncology;radiation resistance;radiation response;Radiation therapy;Radiogenomics;radioresistant;Regimen;Relapse;Research Project Grants;Resistance;response;Sampling;single cell genomics;Specific qualifier value;stem;Testing;Time;Tissues;Toxic effect;Transcend;treatment response;tumor;tumor heterogeneity;tumor microenvironment;Tumor Tissue;Variant

PROJECT_TITLE: Research Project 1: Diffuse Midline Glioma


ED_INST_TYPE: SCHOOLS OF NURSING

NIH_SPENDING_CATS: Bioengineering;Cancer;Chronic Pain;Clinical Research;Clinical Trials and Supportive Activities;Dental, Oral, and Craniofacial Disease;Dissemination and Implementation Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Pain Research;Rare Diseases;Rural Health

ORG_CITY: HOUSTON

ORG_NAME: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON

PHR: PROJECT NARRATIVE This project is relevant to public health by identifying implementation and technology standards for effective, widespread use of the ePVA that are applicable to all digital health tools. Thus, this proposed research aligns with the National Cancer Institute’s mission by advancing scientific knowledge and helping people live longer, healthier lives.

PI_NAMEs: VAN CLEAVE, JANET H (contact)

PROGRAM_OFFICER_NAME: D'ANGELO, HEATHER

PROJECT_TERMS: access disparities;acute care;Adoption;Architecture;arm;cancer care;Cancer Center;care systems;chemotherapy;chronic pain;Clinical;Combined Modality Therapy;common symptom;completed suicide;Comprehensive Cancer Center;cost;data integration;Deglutition;design;Diagnosis;digital health;Documentation;Early Diagnosis;Effectiveness;effectiveness evaluation;effectiveness testing;Electronic Health Record;electronic health record system;Electronics;Emergency department visit;Enteral Feeding;experience;Food;Fox Chase Cancer Center;Goals;Head and Neck Cancer;head and neck cancer patient;health related quality of life;Healthcare;Hospitalization;Human;hybrid type 1 study;implementation strategy;improved;Individual;Institution;interoperability;Intervention;Interview;Investigation;Kansas;Knowledge;Literature;Logic;Maintenance;Malignant Neoplasms;Measures;Medical;Medical center;Methods;Mission;Monitor;National Cancer Institute;New York;Oncology;Operative Surgical Procedures;Outcome;Pain;Participant;patient engagement;patient oriented;Patients;Persons;point of care;Population;Population Heterogeneity;primary endpoint;primary outcome;Public Health;Radiation therapy;randomized, clinical trials;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recommendation;Reporting;Research;Rural Population;rural setting;satisfaction;Scientific Advances and Accomplishments;secondary outcome;Site;Smell Perception;Social Functioning;Standardization;statistics;support tools;Symptom Burden;symptom management;symptomatic improvement;Symptoms;Taste Perception;Technology;theories;Time;tool;treatment as usual;United States;United States Centers for Medicare and Medicaid Services;Universities;Urban Population;urban setting;usability;usual care arm;Variant;Visit

PROJECT_TITLE: Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-HSS-P(90)S]


ADMINISTERING_IC: EB

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

ORG_CITY: AMHERST

ORG_DEPT: BIOMEDICAL ENGINEERING

ORG_NAME: STATE UNIVERSITY OF NEW YORK AT BUFFALO

PHR: Relevance to Public Health: The successful outcome of the proposed project will provide a whole new imaging technique with highly efficient acquisition technique and RF hardware dedicated to human ligament, tendon and bone MR imaging. With this package of novel hardware and software, people can visualize the invisible structures in regular MR technology. This would advance and benefit the biomedical research and clinical diagnosis on musculoskeletal diseases, joint/cartilage disorders, connective tissue diseases and injuries, rheumatism, osteoporosis, and complications associated with diabetes in lower and upper extremities.

PI_NAMEs: LI, XIAOJUAN ;ZHANG, XIAOLIANG  (contact)

PROGRAM_OFFICER_NAME: WANG, SHUMIN

PROJECT_TERMS: absorption;Acceleration;Address;Anatomy;Awareness;Base Sequence;Biomedical Engineering;Biomedical Research;Body part;bone;bone imaging;calcification;Cartilage Diseases;Clinical;clinical diagnosis;clinically relevant;Collagen;Computer software;Connective Tissue;Connective Tissue Diseases;cortical bone;Dedications;design;design and construction;design verification;Development;Diabetes Mellitus;Diagnosis;diagnostic tool;diagnostic value;disability;Disease;Disease Management;Evaluation;flexibility;foot;Frequencies;Hand;high resolution imaging;Human;human subject;human tissue;Image;Imaging Device;imaging modality;imaging scientist;Imaging Techniques;improved;in vivo;Injury;Interdisciplinary Study;Involuntary Movements;Joints;Knee;ligament injury;Ligaments;Limb structure;Lower Extremity;Magnetic Resonance Imaging;Magnetism;Methods;millisecond;Minnesota;Morphologic artifacts;Morphology;Motion;Musculoskeletal;Musculoskeletal Diseases;musculoskeletal imaging;Musculoskeletal System;Natural graphite;non-invasive imaging;novel;Osteoporosis;Outcome;Pennsylvania;Performance;Periosteum;Persons;Physicians;Predisposition;Printing;Public Health;Relaxation;Reproducibility;Research;Resolution;Rheumatism;Safety;safety assessment;Scanning;Scientist;Shapes;Signal Transduction;Solid;solid state;Specimen;Speed;Structure;substantia spongiosa;System;Techniques;Technology;technology validation;Tendon structure;Testing;Theoretical model;Time;tissue injury;Tissues;tool;transmission process;ultra high resolution;United States;Universities;Upper Extremity;Visualization;wearable device

PROJECT_TITLE: Enhanced MR for morphological characterization of ligaments, tendons and bone

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-SBIB-H(55)]


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Radiation Oncology

PHR: Narrative Quantitative imaging of α-particle emitters is important for dosimetry needed to optimize patient therapy. Well validated methods for such imaging do not currently exist. We will develop and validate such methods while also considering different approaches to reduce the number of imaging sessions required for accurate dosimetry of αRPT

PI_NAMEs: DU, YONG  (contact)

PROJECT_TERMS: 3-Dimensional;absorption;Address;Adopted;Alpha Particle Emitter;Alpha Particles;animal data;animal-assisted therapy;Area;Biological Response Modifier Therapy;cancer cell;cancer therapy;Characteristics;chemotherapy;Clinical;clinical practice;Clinical Trials;Collaborations;Complex;cost;Data;Data Collection;Daughter;design;Development;Diagnostic Imaging;Diagnostic Procedure;Discipline of Nuclear Medicine;Disseminated Malignant Neoplasm;Distributional Activity;Dose;dosimetry;Drug Kinetics;Gamma Rays;Goals;Histologic;Image;image reconstruction;imaging modality;improved;improved outcome;in vivo;individualized medicine;Knowledge;Linear Energy Transfer;Maximum Tolerated Dose;Measures;member;Methodology;Methods;Modality;Modeling;Monitor;optical spectra;Organ;Outcome;patient population;patient response;patient screening;Patient Selection;Patient-Focused Outcomes;Patients;PET/CT scan;Phase;Photons;Physics;Procedures;Program Research Project Grants;Property;Protocols documentation;quantitative imaging;Radiobiology;Radioisotopes;Radiopharmaceuticals;reconstruction;Resistance;response;screening;single photon emission computed tomography;Surface;System;Techniques;Testing;therapy outcome;Time;Tissues;Toxic effect;Treatment Efficacy;treatment optimization;treatment planning;Treatment Protocols;tumor;Uncertainty;Validation;Work;X-Ray Computed Tomography

PROJECT_TITLE: Alpha-emitter Imaging for Dosimetry and Treatment Planning


ADMINISTERING_IC: HG

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

IC_NAME: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

NIH_SPENDING_CATS: Bioengineering;Data Science;Genetics;Human Genome;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Stem Cell Research;Stem Cell Research - Embryonic - Human

ORG_CITY: PITTSBURGH

ORG_DEPT: BIOSTATISTICS & OTHER MATH SCI

ORG_NAME: CARNEGIE-MELLON UNIVERSITY

PHR: PROJECT NARRATIVE The proposed research is relevant to public health because it will enhance our understanding of nuclear genome organization and functions that are increasingly being linked to health and disease. Because we develop tools to disseminate this information and enable others to work with our data and their own data, we will also bring nuclear architecture to bear on a broad range of ongoing health related research. Thus, the proposed research is relevant to NIH’s mission that seeks to obtain fundamental knowledge that will help to improve human health.

PI_NAMEs: ALBER, FRANK ;BELMONT, ANDREW STEVEN;MA, JIAN  (contact);WU, CHAO-TING

PROGRAM_OFFICER_NAME: PAZIN, MICHAEL J

PROJECT_TERMS: Address;Architecture;Binding;Biochemical;Cell Cycle;cell fixing;Cell Nucleus;Cell Physiology;cell type;Cells;Chromatin;Chromatin Loop;Chromatin Structure;Chromosome Mapping;Chromosome Structures;Chromosomes;Cleavage Under Targets and Release Using Nuclease;Collaborations;Communities;computer framework;computerized tools;Computing Methodologies;Cytology;Data;data exploration;data integration;Data Set;data tools;Development;Disease;DNA Replication Timing;empowerment;experimental study;Formulation;Gene Expression;Genetic;Genetic Transcription;Genome;genome-wide;genomic data;Genomics;Goals;Health;histone modification;Human;Image;imaging modality;improved;insight;interactive visualization;Interphase Chromosome;Intuition;Knowledge;Link;machine learning algorithm;Maps;Measurement;Measures;Methods;Microscopy;Mission;Modality;Modeling;Molecular;multi-scale atlas;multimodal data;Multimodal Imaging;multimodality;multiple data types;multiscale data;Nuclear;Nuclear Lamina;Nuclear Structure;Organelles;Outcome;Output;Phase;Population;Precision Run-On Sequencing;predictive modeling;Production;Public Health;Research;Research Personnel;Resolution;response;Role;spatiotemporal;Structure;superresolution microscopy;Technology;Three-Dimensional Imaging;tool;transcription factor;transcriptome sequencing;United States National Institutes of Health;user-friendly;Validation;Variant;Visualization;whole genome;Work

PROJECT_TITLE: Multiscale Analyses of 4D Nucleome Structure and Function by Comprehensive Multimodal Data Integration

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-BST-T(50)R]


NIH_SPENDING_CATS: Cancer;Data Science;Genetics;Neuroblastoma;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Precision Medicine;Radiation Oncology;Rare Diseases

PI_NAMEs: CHOWDHURY, DIPANJAN  (contact)

PROJECT_TERMS: Acute;Address;adverse outcome;Artificial Intelligence;Biological;Biological Markers;Biological Models;Biology;Blood specimen;Cancer Biology;Carrier Proteins;case control;Catalogs;Cells;Child;Childhood;Classification;Clinical;Clinical Trials;cohort;Cohort Studies;Collaborations;Combined Modality Therapy;Computer Models;Coupled;Data;Data Science;design;Development;Diagnosis;Disease;Disease-Free Survival;DNA;DNA Repair;dosimetry;Education;Endothelial Cells;Evaluation;Exposure to;Failure;Functional disorder;Funding;Gene Expression Profile;Genetic Transcription;genetic variant;Genomics;Goals;Growth;Heterogeneity;high risk;Image;Immune;improved;improved outcome;innovation;insight;irradiation;large datasets;Late Effects;Long-Term Survivors;Malignant Childhood Neoplasm;Measures;Mediating;Medical;metaiodobenzylguanidine;MicroRNAs;Modality;Molecular;molecular marker;neoplastic cell;Neuroblastoma;Nodal;Normal tissue morphology;novel;Oncology;Outcome;Patients;Pediatric Oncologist;Pediatric Oncology Group;peripheral blood;phase III trial;Play;Point Mutation;Population;Populations at Risk;predicting response;predictive marker;prognostic;prophylactic;protein expression;psychologic;Radiation;Radiation Dose Unit;Radiation Oncology;radiation response;Radiation therapy;Radiation Tolerance;Radiobiology;radiomics;Radiopharmaceuticals;Randomized;randomized trial;Relapse;Research Project Grants;Resected;Resistance;Resources;response;Role;Sampling;Scientist;Second Primary Neoplasms;serial imaging;Series;skills;Specimen;Stromal Cells;Survivors;Systemic disease;Targeted Radiotherapy;Testing;theranostics;Thyroid Gland;Time;Toxic effect;transcriptomics;Treatment Failure;treatment strategy;tumor;tumor DNA;tumor heterogeneity;Tumor Markers;tumor microenvironment;Work

PROJECT_TITLE: Research Project 2: Neuroblastoma


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Brain Disorders;Clinical Research;Dementia;Genetics;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Precision Medicine;Prevention;Racial and Ethnic Minority Health Research;Sleep Research

ORG_NAME: BETH ISRAEL DEACONESS MEDICAL CENTER

PHR: PROJECT NARRATIVE Sleep disorders, such as sleep disordered breathing, short sleep duration, and insomnia, are associated with Alzheimer's Disease and Related Dementia, and cognitive aging phenotypes that precede them. We will study the association between major sleep disorders and harmonized global cognitive aging phenotypes across three cohorts of diverse U.S. populations and generalize these associations to AD phenotypes in cohorts from the Rush Alzheimer's Disease Center. We will develop polygenic risk scores for sleep phenotypes, study genetic- and omics-based mechanism by which suboptimal sleep accelerates cognitive aging, and develop risk prediction models using sleep-related genetics and omics measures.

PI_NAMEs: SOFER, TAMAR  (contact)

PROGRAM_OFFICER_NAME: PERCY-LAURRY, ANTOINETTE LOIS

PROJECT_TERMS: Acceleration;Aging;aging related;Alzheimer's Disease;Alzheimer's disease related dementia;Atherosclerosis Risk in Communities;Biological;Biological Markers;biomarker identification;Clinical Research;Cognitive;Cognitive aging;cognitive change;cognitive function;cognitive performance;cohort;Collaborations;cost effective;Data;Data Set;Dementia;dementia risk;Development;Disease;Disease Progression;Disparity;Ensure;ethnic minority;Ethnic Origin;Gender;gender minority;Gene Expression;Genetic;Genetic Determinism;genetic predictors;Genetic Predisposition to Disease;Genetic Risk;Genetic study;genome wide association study;Health;Hispanic Community Health Study;Hispanic Community Health Study/Study of Latinos;Impaired cognition;improved;Individual;Intervention;Investments;Latino Population;Longitudinal cohort study;Measures;Mediating;Mediation;Mediator;Mendelian randomization;metabolomics;Methodology;Modeling;Multi-Ethnic Study of Atherosclerosis;novel;Obstructive Sleep Apnea;Pathway interactions;Phenotype;polygenic risk score;Population;Population Heterogeneity;precision medicine;Precision Medicine Initiative;Process;Proteomics;Race;racial minority;research study;Risk;Risk Factors;risk prediction model;risk stratification;Sample Size;Sampling;Sleep;Sleep Apnea Syndromes;Sleep Disorders;Sleeplessness;Structure;United States National Institutes of Health;Work

PROJECT_TITLE: Using polygenic risk scores and omics to study how suboptimal sleep accelerates cognitive aging in diverse populations

STUDY_SECTION: AIMR

STUDY_SECTION_NAME:
Aging, Injury, Musculoskeletal, and Rheumatologic Disorders Study
Section[AIMR]


NIH_SPENDING_CATS: Bioengineering;Clinical Research;Clinical Trials and Supportive Activities;Eye Disease and Disorders of Vision;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Preterm, Low Birth Weight and Health of the Newborn;Rare Diseases

ORG_CITY: LAKE OSWEGO

ORG_NAME: SILOAM VISION, INC.

ORG_STATE: OR

PHR: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness, which is most often preventable when accurate and timely ROP diagnosis can be provided. Artificial intelligence (AI) has the potential to provide immediate, expert-level clinical diagnosis to medical images, such as digital fundus images taken as part of ROP screening in neonatal care units. In this application, Siloam Vision will perform the necessary steps required to seek regulatory approval for the first AI algorithm for ROP diagnosis, which is the first step in making this technology available worldwide and potentially reducing the number of children who go blind from ROP.

PI_NAMEs: CAMPBELL, JOHN PETER;JONAS, KARYN  (contact)

PROGRAM_OFFICER_NAME: LEE, PAEK-GYU

PROJECT_TERMS: accurate diagnosis;Algorithms;Artificial Intelligence;artificial intelligence algorithm;Award;blind;Blindness;Blood Vessels;Caring;Case Study;Child;Childhood;Classification;Clinical;clinical diagnosis;Clinical Research;cloud based;Code;Collaborations;Computer software;Country;Custom;Data;Data Management Resources;design;detection sensitivity;Devices;Diagnosis;diagnosis standard;Diagnostic;diagnostic tool;digital;Disease;disease classification;disease diagnosis;Dropout;Early Diagnosis;Early treatment;Ensure;expedited review;Eye;Funding;fundus imaging;Fundus photography;Goals;Health;Image;image processing;improved;improved outcome;India;Infrastructure;International;Investments;low and middle-income countries;Manufacturer;Marketing;Medical;Medical Imaging;medically underserved;meetings;Mission;neonatal care;Oregon;Output;Paper;Performance;Phase;prevent;primary outcome;Privatization;Process;Provider;Reader;Reference Standards;Research;Resources;retinal imaging;Retinopathy of Prematurity;Science;screening;secondary outcome;segmentation algorithm;Services;Severities;Small Business Innovation Research Grant;software as a medical device;software development;Specificity;Speed;Standardization;System;Technology;Telemedicine;Testing;Training;transfer learning;underserved area;United States Food and Drug Administration;Universities;Update;Validation;Vision;Work

PROJECT_TITLE: Validation of artificial intelligence (AI) based software as medical device (SaMD) for retinopathy of prematurity (ROP)


ADMINISTERING_IC: AR

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Physical Injury - Accidents and Adverse Effects;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: SAN FRANCISCO

ORG_DEPT: ORTHOPEDICS

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PHR: Narrative: Failures in bone fracture healing can occur due to disruptions to cellular processes at different phases of the healing process. This proposal examines cellular fate decisions that occur at different times in the healing process to produce the tissues that successfully heal the injured bone.

PI_NAMEs: MARCUCIO, RALPH S (contact)

PROGRAM_OFFICER_NAME: CHEN, FAYE H

PROJECT_TERMS: Ablation;Abnormal Cell;Adopted;Adult;Animals;Binding;bone;Bone callus;bone fracture repair;Bone Injury;Cartilage;Cell Compartmentation;Cell Differentiation process;Cell Lineage;Cell Physiology;cell type;Cells;Cephalic;ChIP-seq;Chondrocytes;Cleavage Under Targets and Release Using Nuclease;Cre lox recombination system;Data;directed differentiation;Embryo;Environment;Event;experimental study;Failure;Fibrosis;Fracture;FRAP1 gene;Genomics;healing;Individual;inducible Cre;Injury;injury and repair;intramembranous bone formation;Knockout Mice;Label;loss of function;Maintenance;Mechanics;Mediating;Metaplasia;Methods;Molecular;mTOR Inhibitor;Mus;mutant;Natural regeneration;Neural Crest Cell;NF1 gene;osteoblast differentiation;Osteoblasts;osteochondral tissue;osteogenic;Outcome;paligenosis;Pathway interactions;Periosteal Cell;Periosteum;Phase;Physiologic Ossification;Play;Population;Process;programs;Proto-Oncogene Proteins c-akt;Publishing;reconstitution;recruit;response;Role;Series;Signal Transduction;Sirolimus;Site;stem cell differentiation;stem cell division;stem cell self renewal;stem cells;stemness;Systems Biology;Testing;Tissues;transcription factor;Transcriptional Activation;Work;wound

PROJECT_TITLE: Cell Transitions during Bone Fracture Healing


NIH_SPENDING_CATS: Bioengineering;Cancer;Kidney Disease;Precision Medicine;Radiation Oncology

PHR: Project Narrative – Project 2 Radiopharmaceutical therapy with alpha-particle emitters (RPT) provides a unique and effective treatment for cancer in its advanced stages. In the development of patient-specific treatment planning for RPT, one objective is to ensure that the radiation dose to normal tissues and organs approaches, but remains below, thresholds for toxicity. The primary objective of this project is to develop microscale radionuclide S-values which will permit clinically feasible methods for assessing tissue-level dosimetry of alpha-particles in individual patients.

PI_NAMEs: BOLCH, WESLEY E (contact)

PROJECT_TERMS: 3-Dimensional;absorption;Address;Alpha Particle Emitter;Alpha Particles;Anatomic Models;Anatomy;Beta Particle;Blood;Blood capillaries;Bone Marrow;cancer radiation therapy;cancer therapy;Cells;Chemoresistance;Clinical;Clinical Trials;Development;digital imaging;Disease;Disseminated Malignant Neoplasm;Dose;dosimetry;effective therapy;Family suidae;Freezing;Future;Generations;Geometry;Goals;Harvest;Hemorrhage;Histology;Human;human imaging;Image;in vivo;Individual;individual patient;individualized medicine;interest;interpatient variability;Kidney;kidney cortex;Kupffer Cells;Label;Laboratory mice;Lacrimal gland structure;Libraries;Linear Energy Transfer;Liver;Lobe;Lobule;Lung;Marrow;Methodology;Methods;Microanatomy;microCT;Miniature Swine;Modeling;Mus;neoplastic cell;Nephrons;Normal tissue morphology;novel;Organ;Organ Model;particle;Pathology;Patients;Photons;Population;porcine model;Pre-Clinical Model;Predisposition;preservation;programs;Publishing;Radiation Dose Unit;radiation resistance;Radiobiology;Radioisotopes;Radiopharmaceuticals;Risk;Risk Assessment;Salivary Glands;Series;Sinus;Site;skeletal;Small Intestines;soft tissue;Source;Specimen;Structure;Systemic Therapy;targeted treatment;Testing;three-dimensional modeling;Time;Tissue Model;tissue preparation;Tissues;tool;Toxic effect;treatment planning;tumor;Uncertainty;validation studies;Work

PROJECT_TITLE: Microscale Radionuclide S-values for αRPT


NIH_SPENDING_CATS: Bioengineering;Cancer;Cancer Genomics;Data Science;Genetics;Human Genome;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Neuroblastoma;Neurosciences;Pediatric;Pediatric Cancer;Radiation Oncology;Rare Diseases

PI_NAMEs: MICHOR, FRANZISKA  (contact)

PROJECT_TERMS: access restrictions;Address;Age;analysis pipeline;Anatomy;Artificial Intelligence;Biological;Biological Assay;Blood flow;Cancer Biology;cancer genomics;Cells;Clinical;clinically significant;Clonal Evolution;Collaborations;Communities;Complex;Computer Models;Computing Methodologies;Data;Data Collection;data exchange;data hub;data integrity;data management;data repository;Data Science;Data Science Core;Data Security;Data Set;Data Storage and Retrieval;Databases;design;diffuse midline glioma;DNA Repair;Dose;dosimetry;Ensure;Epigenetic Process;Evolution;exome;experience;Face;Funding;genomic data;Genomics;Goals;Grant;Image;Immunofluorescence Immunologic;improved;individual patient;Infrastructure;interest;Link;Malignant Childhood Neoplasm;Malignant Neoplasms;member;metaiodobenzylguanidine;Methodology;Methods;miRNA expression profiling;Modeling;Molecular;Natural Language Processing;neoplastic cell;Neuroblastoma;Neuroepithelial, Perineurial, and Schwann Cell Neoplasm;novel;Outcome;Patients;Pediatric Neoplasm;Peripheral Blood Involvement;Population;profiles in patients;Publishing;radiation effect;Radiation Oncology;radiation resistance;radiation response;Radiation therapy;radiomics;Radionuclide therapy;repository;Research Personnel;Resistance;Resource Sharing;Resources;single cell ATAC-seq;single-cell RNA sequencing;Specimen;Structure;structured data;System;The Cancer Genome Atlas;Training;transcriptome sequencing;transcriptomics;treatment planning;tumor;tumor heterogeneity;tumor microenvironment;Tumor Tissue;Weight;whole genome;Work

PROJECT_TITLE: Shared Resource Core 1: Molecular Data Science and Advanced Dosimetry


NIH_SPENDING_CATS: Cancer

ORG_CITY: CHICAGO

ORG_NAME: UNIVERSITY OF CHICAGO

ORG_STATE: IL

PHR: NARRATIVE The African Cancer Leaders Institute (ACLI) is a “meeting within a meeting” designed to coincide with the AORTIC 2023 conference, “Cancer in Africa: Implementation, Workforce, and Opportunities” in Dakar, Senegal, November 3-8, 2023.The ACLI provides an intellectually stimulating platform to propel emerging global cancer leaders from Africa and the US with intensive trainings, mentorship, and networking opportunities with the goal to foster innovative cancer research leadership in Africa. For this renewal application, we have incorporated a mini-Retreat at a African Regional Cancer Conference where ACLI Alums can interact with AORTIC Council Members and participate in planning future AORTIC activities.

PI_NAMEs: OLOPADE, OLUFUNMILAYO F. (contact)

PROGRAM_OFFICER_NAME: ALARO, JAMES R

PROJECT_TERMS: Advocacy;Africa;African;aluminum sulfate;anti-cancer research;Area;Award;brain circulation;cancer therapy;career;career development;Clinical;clinical development;Clinical Trials;cohort;Collaborations;Competence;Country;design;Development;Early identification;Education;Electronic Medical Records and Genomics Network;Emerging Technologies;Ethics;Evaluation;experience;Faculty;forging;Fostering;Foundations;Friends;Funding;Future;Generations;Genetic;Genomics;Goals;Grant;improved;Income;Individual;innovation;Knowledge;Leadership;leadership development;Learning;lectures;Location;Malignant Neoplasms;meetings;member;Mentors;Mentorship;Minority;novel strategies;outreach;Participant;Pathology;peer;peer coaching;Persons;Policies;Portuguese;Productivity;programs;Publications;Publishing;Records;recruit;Regional Cancer;Reporting;Research;research and development;Research Personnel;Research Training;Role;Senegal;symposium;Training;Translating;Travel;United States National Institutes of Health;Woman

PROJECT_TITLE: Africa Cancer Leaders Institute


NIH_SPENDING_CATS: Cancer;Clinical Research;Genetics;Pediatric;Pediatric Cancer;Rare Diseases

PHR: PROJECT NARRATIVE Ewing sarcoma is an aggressive bone and soft tissue cancer impacting children worldwide, and a better understanding of the underlying biology contributing to this disease is needed to enable more informed risk stratification, treatment, and screening approaches. I previously found that pathogenic germline variants in FANCC and other DNA damage repair genes are uniquely enriched among patients with Ewing sarcoma relative to other pediatric sarcoma subtypes. This proposal aims to comprehensively evaluate the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis through an integrated evaluation of germline and tumor genomics, with the goals of informing clinical trial priorities for Ewing sarcoma and having high relevance to the management of other pediatric cancers.

PI_NAMEs: GILLANI, RIAZ  (contact)

PROGRAM_OFFICER_NAME: LIM, SUSAN E

PROJECT_TERMS: Adolescent;Biological;Biological Assay;Biological Factors;Biological Markers;Biology;Bone Tissue;cancer predisposition;Cell Line;Cells;Child;childhood sarcoma;Clinical Trials;clinically relevant;cohort;Combined Modality Therapy;Complex;Computational Biology;Data Set;Development;Disease;DNA Damage;DNA Repair;Evaluation;Ewings sarcoma;EWSR1 gene;Fibroblasts;Foundations;Gene Fusion;gene repair;Genetic;Genetic Complementation Test;Genetic Predisposition to Disease;Genomic Instability;genomic signature;Genomics;Genotoxic Stress;Germ Lines;Germ-Line Mutation;Goals;Heterozygote;homologous recombination;improved;In Vitro;Inherited;insight;Investigation;Knowledge;Link;loss of function;Malignant Childhood Neoplasm;Malignant Neoplasms;Matched Case-Control Study;Mediator;Mentorship;Mesenchymal;Mesenchymal Stem Cells;Mitomycin C;Modeling;Molecular;Morbidity - disease rate;Mutation;Nonhomologous DNA End Joining;novel;novel strategies;Parents;Pathogenesis;Pathogenicity;Patients;Pattern;Pharmacotherapy;Phenotype;predicting response;Predisposition;proband;Process;prognostic;programs;Recurrent disease;Relapse;Reporter;Research Proposals;response;risk prediction;risk stratification;risk variant;Role;screening;skills;soft tissue;targeted agent;Therapeutic;Tissue-Specific Gene Expression;treatment response;tumor;tumorigenesis;Variant;Work

PROJECT_TITLE: Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment

STUDY_SECTION_NAME: Career Development Study Section (J)[NCI-J]


PHR: PROJECT NARRATIVE We propose a cellular and functional sub-unit-based dosimetry model for organs at risk for a more accurate assessment and prediction of response and toxicity in -particle radiopharmaceutical therapy of cancer. Radiopharmaceutical/Organ combination-specific pharmacokinetic data will be acquired for translating macroscopic activity measurements to relevant sub-organ (standardized) absorbed dose.

PI_NAMEs: HOBBS, ROBERT FRANCOIS (contact)

PROJECT_TERMS: absorption;Alpha Particle Emitter;Alpha Particles;Anatomy;Animals;Antibodies;Bone Marrow;cancer therapy;Clinical;clinical practice;Clinical Trials;clinically relevant;Combined Modality Therapy;Data;design;Dose;Dose Limiting;dosimetry;Drug Kinetics;ERBB2 gene;Family suidae;FDA approved;FOLH1 gene;Fractionation;Goals;Human;Image;interest;Kidney;Lacrimal gland structure;Link;Literature;Liver;Lung;Malignant neoplasm of prostate;Malignant Neoplasms;Measurement;Measures;Medicine;Metastatic Neoplasm to the Bone;Methodology;Methods;Microscopic;Miniature Swine;Modality;Modeling;mouse model;Mus;Organ;Organ Model;particle;particle therapy;Patients;Peptides;porcine model;pre-clinical;Pre-Clinical Model;predicting response;Process;programs;Publishing;Radiobiology;Radioisotopes;Radiopharmaceuticals;Reporting;response;Risk;Salivary Glands;single photon emission computed tomography;Small Intestines;small molecule;spatiotemporal;Standardization;targeted delivery;targeted treatment;Testing;Therapeutic;Therapeutic Uses;Time;Toxic effect;Translating;translation to humans;Translations;treatment planning;Uncertainty;United States National Institutes of Health;Work

PROJECT_TITLE: Macro-to-micro (M2µ) Activity Apportionment for αRPT


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Data Science;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Neuroblastoma;Neurosciences;Pediatric;Pediatric Cancer;Radiation Oncology;Rare Diseases

PI_NAMEs: AERTS, HUGO  (contact)

PROJECT_TERMS: Academic Training;Acceleration;Address;Adoption;Algorithmic Analysis;anti-cancer research;Apache;Artificial Intelligence;artificial intelligence algorithm;artificial intelligence method;Artificial Intelligence platform;Biological Assay;Cancer Biology;Cancer Research Project;cancer therapy;Characteristics;Clinic;Clinical;Clinical Data;clinical phenotype;clinical translation;Communities;Community Clinical Oncology Program;Complex;Computer software;Computerized Medical Record;Data;Data Analyses;Data Commons;Data Science;Data Science Core;Data Set;data streams;electronic data;Ensure;experience;Goals;Heterogeneity;Image;imaging biomarker;imaging probe;improved;Industry;Informatics;Infrastructure;Intelligence;Investigation;Investments;Knowledge;Late Effects;Malignant Childhood Neoplasm;Malignant Neoplasms;Measures;Medical;Medical Imaging;Medicine;Methods;Modeling;Molecular;Multiomic Data;multiple omics;Natural Language Processing;Neuroblastoma;open source;Patients;Pattern;Phenotype;Prediction of Radiation Response;Preparation;programs;quantitative imaging;Radiation;radiation during childhood;Radiation Oncology;radiation resistance;radiation response;Radiation therapy;radiological imaging;radiomics;Reproducibility;Research;Research Project Grants;Research Support;Resource Sharing;Resources;response;Scientific Advances and Accomplishments;Semantics;Standardization;synergism;Technology;Text;The Cancer Imaging Archive;tool;Toxic effect;Training;treatment response;tumor;tumor heterogeneity;usability

PROJECT_TITLE: Shared Resource Core 2: Clinical Artificial Intelligence Core


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Drug Abuse (NIDA only);Lung;Neurosciences;Opioid Misuse and Addiction;Opioids;Sleep Research;Substance Misuse

ORG_DEPT: PSYCHIATRY

PHR: The proposed longitudinal, observational study will use highly rigorous methodology to determine the associations of sleep and proxy measures of circadian rhythms with non-medical opioid use among individuals in opioid use disorder (OUD) treatment. This study will also investigate affective processes that might enhance our understanding of the relationship between sleep/circadian rhythm phenotypes and OUD treatment outcomes. This mechanistic research will improve our scientific understanding of factors influencing OUD treatment, and inform future clinical intervention research aimed at improving the quality of OUD treatment.

PI_NAMEs: HUHN, ANDREW S (contact);RABINOWITZ, JILL ALEXANDRA

PROGRAM_OFFICER_NAME: NAIR, SUNILA GOPI

PROJECT_TERMS: actigraphy;addiction;Affect;Affective;alcohol use disorder;Animal Model;Apnea;Architecture;Buprenorphine;buprenorphine treatment;Central Sleep Apnea;Chronic;circadian;Circadian Rhythms;Clinical;clinically relevant;clinically significant;combat;community collaboration;craving;Data;Development;Devices;Disease;Dose;Drug usage;Ecological momentary assessment;Enrollment;Frequencies;Future;Goals;Health;high risk;Human;human model;Hydrocortisone;Hypoxia;illicit opioid;improved;improvement on sleep;indexing;Individual;Intervention;Intervention Studies;Intervention Trial;Knowledge;Link;Longitudinal Studies;Longitudinal, observational study;longitudinal, prospective study;Measures;Mediating;medication for opioid use disorder;Mental Health;Methadone;methadone treatment;Methodology;negative affect;novel;novel therapeutics;Obstructive Sleep Apnea;Opioid;opioid epidemic;opioid misuse;opioid use;opioid use disorder;Outcome;Overdose;Participant;Pathway interactions;Patient Self-Report;Pattern;Persons;Pharmaceutical Preparations;Phase;Phenotype;Polysomnography;Process;Provider;Proxy;Public Health;Recovery;Research;research and development;Rest;return to use;Risk;Rodent;saliva sample;secondary analysis;Severities;Sleep;Sleep Apnea Syndromes;Sleep Architecture;Sleep disturbances;Sleep Stages;Sleeplessness;Stress;Substance Use Disorder;Time;Toxicology;Translational Research;Treatment outcome;Urine;Work;Wrist

PROJECT_TITLE: Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomes


NIH_SPENDING_CATS: Cancer;Data Science;Pediatric;Pediatric Cancer;Radiation Oncology;Rare Diseases

PI_NAMEs: BERBECO, ROSS I. (contact)

PROJECT_TERMS: Area;Artificial Intelligence;Attention;Cancer Biology;cancer care;Categories;Cells;Cementation;Clinical;Collection;Communities;Competence;Complement;Couples;data hub;Data Science;Dedications;Development;Development Plans;didactic education;Discipline;Education;education resources;Educational process of instructing;Educational Status;Environment;equity, diversity, and inclusion;Faculty;Family;Fostering;Funding;Future;Generations;Goals;Grant;hands-on learning;health care disparity;imaging science;Individual;innovation;interdisciplinary approach;interdisciplinary collaboration;Interdisciplinary Education;Knowledge;knowledge integration;Learning;lectures;Libraries;Link;Malignant Childhood Neoplasm;Medicine;member;Mentors;Mentorship;Methods;minority trainee;Mission;Modeling;Modernization;multidisciplinary;next generation;novel;outreach;Participant;patient population;Pediatric Oncology;posters;programs;prospective;Radiation;radiation during childhood;Radiation Oncology;Radiation Physics;radiation resistance;radiation response;Radiobiology;Research;Research Personnel;Research Project Grants;Resources;Schools;Science;Scientist;Series;Site;skill acquisition;skills;social;Structure;Training;Training and Education;Transcend;Travel;Underrepresented Minority;underrepresented minority student;Underserved Population;United States National Institutes of Health;web site

PROJECT_TITLE: Cross-Training Core (ROBIN-NEST)


ADMINISTERING_IC: HS

ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

IC_NAME: AGENCY FOR HEALTHCARE RESEARCH AND QUALITY

ORG_CITY: NEW ORLEANS

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: TULANE UNIVERSITY OF LOUISIANA

ORG_STATE: LA

PHR: Project Narrative  Collaboration between health systems and community partners have the potential to effectively address the social determinants of health and improve population health equity. The community benefit program for not- for-profit hospitals can be leveraged to require multi-sectoral collaboration and provides a natural experiment to understand whether multi-sectoral collaboration if effective. This proposal, through a supervised mentorship and training program, aims to examine the impact of collaboration between hospitals, health departments, and other community partners on population health equity and hospital investment in SDOH.

PI_NAMEs: SANTOS, TATIANE  (contact)

PROGRAM_OFFICER_NAME: WILLIS, TAMARA

PROJECT_TITLE: Not-For-Profit Hospital Community Benefit: Multi-Sectoral Collaboration in Local Health Planning to Improve Population Health, Equity, and Hospital Investment in the Social Determinants of Health

STUDY_SECTION: HCRT

STUDY_SECTION_NAME: Healthcare Research Training [HCRT]


ORG_NAME: SAROS THERAPEUTICS INC

PHR: Narrative: The proposed research is most relevant to public health as these studies will generate new fundamental knowledge in the development of a novel cancer immunotherapy and will advance one promising new therapy in preparation for clinical trials. The SNP nanoparticle formulation will improve the transformation of “cold” into “hot” tumors by prolonging stimulation of the STING pathway leading to a robust immune response in the tumor microenvironment. This approach may be efficacious as a monotherapy in some cancers and will also augment the activity of other immunotherapies, particularly immune checkpoint inhibitors.

PI_NAMEs: JOHNSON, RICHARD  (contact)

PROGRAM_OFFICER_NAME: POND, MONIQUE ADRIANNE

PROJECT_TERMS: Acceleration;Address;Agonist;anti-tumor immune response;Antitumor Response;Benchmarking;Biodistribution;Biological;Biopsy Specimen;Blood Chemical Analysis;Breast Cancer Patient;cancer immunotherapy;Cancer Patient;cancer type;Cell membrane;cell type;Cells;Characteristics;clinic ready;Clinical;clinical development;Clinical Research;Clinical Trials;comparative efficacy;Complex;Contracts;Cytosol;Data;Dendritic Cells;design;Development;Dinucleoside Phosphates;Disseminated Malignant Neoplasm;Dose;drug development;Drug Kinetics;Encapsulated;Ensure;Enzymes;Exclusion;Excretory function;Exhibits;experience;Filtration;Formulation;Funding;Future;Gene Activation;Generations;Half-Life;Haplotypes;Head and Neck Squamous Cell Carcinoma;healthy volunteer;Human;immune activation;immune checkpoint blockade;Immune checkpoint inhibitor;Immune response;Immunotherapy;improved;improved outcome;Incubated;Inflammation;Injections;Interferon-beta;Interferons;Knowledge;large scale production;Lead;lead candidate;Legal patent;Liver;Macrophage;Malignant Neoplasms;Manganese;manufacture;manufacturing organization;manufacturing scale-up;Mediating;Metabolism;Methods;Michigan;Microfluidics;Modeling;monocyte;Mus;Myeloid Cells;nano;nanoformulation;nanoparticle;Nanotechnology;Natural Killer Cells;Nature;Neoplasm Metastasis;nonhuman primate;novel;novel therapeutics;Oryctolagus cuniculus;Pathway interactions;Patient-Focused Outcomes;Patients;Penetration;Periodicity;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;Pharmacodynamics;pharmacokinetics and pharmacodynamics;Phase;Phase I Clinical Trials;Pilot Projects;Plasma;Population;pre-clinical;preclinical study;Preparation;Process;Production;Public Health;Reproducibility;Research;response;Rights;Safety;safety study;Sampling;scale up;Small Business Innovation Research Grant;Solid Neoplasm;Stimulator of Interferon Genes;success;System;T-Lymphocyte;Technology;technology platform;Technology Transfer;Therapeutic;therapeutic candidate;Time;Tissues;Toxicology;triple-negative invasive breast carcinoma;tumor;tumor growth;tumor microenvironment;Universities;uptake;Variant;Work

PROJECT_TITLE: Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation